The study found that 85% of Crohn’s patients who had experienced a reduced or loss of response to Remicade (infliximab) – currently the only FDA-approved biologic treatment for Crohn’s disease – experienced a reduction in disease activity with Humira (adalimumab).
Researchers retrospectively evaluated the safety and efficacy of six months of therapy with Humira in 15 patients with active Crohn’s disease (CD) who experienced a reduced or loss of response to Remicade.
Of the patients who completed the study, 54% had a complete response to treatment with Humira, 31% had a partial response, and 15% were non-responders. Patients with extra-intestinal manifestations of CD (joint pain) improved or resolved their symptoms with Humira treatment, as did one patient who suffered from oral ulcers.
No severe adverse events were observed in this study and there was no evidence of immediate or delayed-type hypersensitivity reactions.